Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs - GBI Research Reports

Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs

Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs - GBI Research Reports
Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs
Published Sep 17, 2011
168 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its latest research Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs, which provides insights into effective innovative strategies adopted by the pharmaceutical and biotechnology industry. The report examines numerous case studies of various R&D strategies such as outsourcing, offshoring, internal reorganization, R&D restructuring, risk sharing, public-private partnerships and others.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Researchs team of experts.

Scope

The scope of this report includes -
- Strategies adopted by pharmaceutical and biotechnology industry participants to succeed in the highly competitive pharmaceutical market
- Analysis of challenges faced by industry participants in increasing R&D output
- Analysis of strategies that have been ineffective in the pharmaceutical industry and those that have failed to achieve objectives
- Analysis on the role of CROs in improving R&D efficiencies in the pharmaceutical industry
- Key M&A activities and licensing agreements that have been aimed at increasing R&D outcomes

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Understand the different types of strategies being adopted in the industry to increase R&D outcomes
- Build effective strategies to improve R&D efficiencies through comprehension of strategies that worked and those that didnt work
- Analyze numerous case studies on various strategies adopted by the pharmaceutical industry to evaluate the best strategies
- Compare strategies adopted in-house to those adopted in-house to evaluate and forecast outcomes

  
Source:
Document ID
GBIHC103MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents46
  List of Tables71
  List of Figures82
Innovative R&D Strategies and Models - Introduction102
  GBI Research Report Guidance102
Current Challenges in the Pharmaceutical R&D - Declining ROI and Stringent Pricing and Reimbursements, a Major Impediment1210
  Declining Return on Investment in R&D121
    Increasing R&D Costs against Declining NME/BLA Approvals during the Period 1995 2010)121
    Reduced Success Rates on R&D for the Pharmaceutical Industry132
    R&D Costs Increasing Against Revenue Growth for the Top 10 Pharma Companies151
  Adverse Pricing and Reimbursement Regime for New Drugs161
    Pressure to Curb Healthcare Costs Driving the Increased Adoption of Stringent Pricing Mechanisms162
    Economic Evaluations Gaining Importance as a Key Parameter for Reimbursement Decisions182
  Generic Competition and Increasing Number of Patent Challenges202
Major Steps Taken by Pharma Companies to Improve R&D Efficiency226
  R&D Components to Concentrate for Increasing Efficiency221
    Decrease Cost Short Term Solution231
    Improve Returns from Same Level of Output Limited Success Potential Solution231
    Increase Output (Number of Drugs) Long Term Solution241
  Network R&D Involving External Partners to Complement Internal R&D Capabilities251
  Establishing Focus on Niche Markets262
Innovative R&D Strategies and Models - Strategic Consolidations289
  Major Industry Consolidations in the Last Decade281
    Teva Cephalon: Focus on Branded Drugs281
      Deal Rationale291
    Novartis Alcon: Diversification301
      Background301
      Deal Rationale301
    Pfizer Wyeth: Safeguarding Revenues against Patent Expiries311
      Background311
      Rationale311
    Roche Genentech: Better Coordination in Product Development321
      Background:321
      Rationale321
    Merck Schering-Plough: Expanding Pipeline Portfolio as well as Presence in High Growth Emerging Markets331
      Background331
      Rationale331
    AstraZeneca MedImmune: Reviving Phase III Pipeline While Accelerating Biologics Strategy341
      Background341
      Rationale351
    Eli Lilly ImClone Systems: Developing a Strong Oncology Pipeline Portfolio to Prevent Revenue Dip after Zyprexa Patent Expiry351
      Background351
      Rationale352
Innovative R&D Strategies and Models Better Lifecycle Management of Existing Drugs3716
  Indication Expansion371
    Case 1: Bayer s Adalat372
    Case 2: Merck s Fosamax392
    Case 3: Eisai s Aciphex/Pariet412
  Extended/Controlled Release Versions431
    Case 1: Johnson &Johnson s Risperdal and Risperdal Consta431
    Case 2: Pfizer s Zithromax and Zmax442
    Case 3: GlaxoSmithKline s Coreg and Coreg Controlled Release (CR)461
  New Formulations471
    Case 1: Eisai s Aricept481
    Case 2: Johnson &Johnson s Concerta492
    Case 3: Takeda s Takepron512
Innovative R&D Strategies and Models Internal Reorganization535
  Restructuring the R&D531
    GlaxoSmithKline Realigning Focus to Vaccines, Consumer Healthcare and Emerging Markets541
    Pfizer Redefining the Research Focus and Outsourcing the Rest551
    AstraZeneca Consolidating R&D Facilities with Narrowed Therapeutic Focus561
    Sanofi Combining Workforce Consolidation with Externalization to Safeguard Future Revenues571
Innovative R&D Strategies and Models Public-Private Partnerships (PPP)5815
  What are Public-Private Partnerships?581
    PPP in R&D in the Pharmaceutical Industry581
  Private-Government Partnerships591
    Innovative Medicine Initiative in Europe592
    Cooperative Research and Development Agreements in the US611
    CRADA for Pharmaceutical R&D611
      Advaxis Signs CRADA with Vaccine Branch of NCI611
      Oxygen Biotherapeutics Signs CRADA with the US Neval Medical Research Center611
      Adamas Signs CRADA with the US Navy621
      Proximagen Group Signs CRADA With NINDS For Naluzotan Development621
    Small Business Innovation Research Program621
      Case Study 1: Optivia Received Grants from the NIH631
      Case Study 2: Avexia Biologics Received Grants from NIH631
      Case Study 3: MBC Pharma Awarded Grant by NIH631
    PPP in India631
    Publicly Funded Medicines in the US631
    Technology Transfer641
      Case Study 1: FluMist Technology Transfer NIAID to Aviron651
      Case Study 2: Collaboration between Firocuz and GSK661
    Laws Enabling Technology Transfer in the US671
      Bayh-Dole Act671
      Stevenson-Wydler Technology Innovation Act671
  Open-source R&D671
  Crowdsourcing681
    Applicability of Crowdsourcing to the Pharmaceutical Industry681
      Sage Bionetworks Received Funding from Quintiles681
      Eli Lilly Announced Phenotypic Drug Discovery Initiative681
  Partnership with the Academia691
    Case Study 1: Pfizer s Centers for Therapeutic Innovation701
    Case Study 2: Collaboration between Pfizer and Washington University711
    Case Study 3: Partnership between Sanofi Aventis and Harvard University721
Innovative R&D Strategies and Models Use of Information Technology in R&D738
  Effective Data Management Is Critical For R&D Productivity731
    CDMS741
    Clinical Data Management Outsourcing741
      Individual Project Outsourcing Model741
      Full Time Equivalent Model751
      Functional Service Provider Model751
    Deals in Clinical Trial Data Management Outsourcing751
      Tata Consultancy Services Eli Lilly751
      Cognizant AstraZeneca761
  Technology Support Inevitable For Personalized Medicine: The Future Class of Medicines771
  Paperless Clinical Trials A Billion Dollar Saving Potential781
    Clinical Trial Management System781
    Electronic Data Capture791
    Using Virtual Technology to Reduce R&D Costs and Time801
Innovative R&D Strategies and Models Outsourcing8115
  Outsourcing R&D811
    Role of CROs in Providing Cost Efficiencies812
  Risk Sharing and Strategic Partnerships831
  Strategic Partnerships Case Study841
    Case 1: Covance s $1.6 Billion Strategic Alliance with Eli Lilly841
    Case 2: PPD s Strategic Collaboration with Merck851
    Case 3: ICON s Partnership with Eli Lilly861
    Case 4: Strategic Alliance between Sanofi Pasteur and Covance861
  Risk Sharing Case Study871
    Case 1: Quintiles Strategic Alliance to Advance Elisa s Oncology Pipeline871
  Profiles of Major Global CROs881
    Quintiles Transnational Corp.881
      Business Description881
      Recent M&A Deals and Strategic Alliances891
    Covance Inc.891
      Business Description901
      Recent M&A Deals and Alliances901
    Pharmaceutical Product Development911
      Business Description911
      Recent M&A Deals and Alliances911
    Charles River Laboratories International921
      Business Description931
      Recent M&A Deals and Alliances931
    PAREXEL International941
      Business Description941
      Recent M&A Deals and Alliances951
Innovative R&D Strategies and Models Outsourcing to Emerging Markets (China, India, Brazil and Russia)9660
  Rationale to Outsource Discovery Research to Emerging Markets961
  Advantages with Emerging Nations in Improvising Discovery Research971
    Case Study 1: Merck s Outsourcing Strategy to India and China971
    Case Study 2: AstraZeneca s Strategic Partnerships with Jubilant, GVK BIO and WuXi982
    Case Study 3: BMS with Biocon1001
    Case Study 4: Novartis Collaboration with Aurigene1001
    Case Study 5: Eli Lilly s Collaboration with Hutchison MediPharma1011
  CROs in China1011
    Classification of CROs in China1011
    Number of CROs in China Based on Types of Services Rendered1021
    CRO Profiles1031
      BOJI Medicine Services Co. Ltd1031
      Giant Med-Pharma Services Inc1041
      InCROM1051
      Pharmaron1061
      Venturepharm Service Group (VPS)1071
      PPD1081
      CCBR-SYNARC1091
      Quintiles1101
      Kendle1111
    Key Issues1121
      Access to a Large Patient Population to Encourage Growth of the CRO Market in China1121
      Easy Recruitment of Patients and Speed of Trials will Drive R&D Outsourcing to China1121
      Increase in Multinational Sites to Conduct Clinical Trials will drive the Clinical Trial Market in China1121
      Slow Regulatory Approvals to Restrain the Growth of CRO Industry in China1131
      Insufficient Communication Platform is a Hurdle to the Growth of the CRO Market in China1131
      Intellectual Property Issues are not Fully Resolved1131
      Lack of in depth Training in Good Clinical Practices (GCP) for Health Care Professionals1131
  CROs in India1141
    Industry Funded Clinical Trials in India in 20111141
    CRO Locations1151
    Service Portfolio and Benchmarking of Indian CROs1161
    CRO Profiles1171
      Reliance Life Sciences1171
      Asian Clinical Trials1181
      Diagnosearch Life Sciences1191
      Clininvent1201
      Synchron Research Services Pvt Ltd1211
      Lambda Therapeutic Research Ltd1221
      GVK Biosciences Pvt Ltd1231
      Sristek1241
      Lotus Laboratories Pvt Ltd1251
      Veeda Clinical Research Ltd1261
      Vimta Labs Ltd1271
      Ecron Acunova1281
      SIRO Clinpharm Pvt Ltd1291
      Catalyst Clinical Services1301
    Key Issues1311
      Cost of Conducting Clinical Trials in India is approximately 55% of the Cost of Conducting a Clinical Trial in the US1311
      Availability of Facilities for Conducting Clinical Trials1311
      Increase in Multinational Sites to Conduct Clinical Trials will drive the Clinical Trial Market in India1321
      Access to a Large Patient Pool1321
      Lack of Training for Clinical Trial Professionals1321
      Quality of Clinical Trial Data1321
      ICH GCP versus Indian GCP1321
      Slow Hiring in the Government Regulatory Bodies1331
      The Need for Proposed Additional Documents for Importing Drugs1331
  CROs in Brazil1341
    Clinical Trials Registered in 20101341
    CRO Profiles1341
      Quintiles1351
      Covance1361
      Kendle1371
      PPD1381
      PRA International1391
      Chiltern1401
      ICON plc.1411
      Omnicare1421
      INC Research1431
      PAREXEL1441
      Intrials1451
      Eurotrials1461
      PGS Medical/Statistics1471
    Key Issues1481
      Access to a Large Patient Pool1481
      Subject Recruitment, Retention and Speed of Trials1481
      Cost Advantage in Brazil1481
      Increase in the Number of FDA Regulated Principal Investigators1491
      Issues Related to Intellectual Property and New Medicine Approval1491
      Cultural and Socioeconomic Factors Could Cause Problems in Conducting Clinical Research1501
  CROs in Russia1501
    Clinical Trials Registered in 20101501
    CRO Profiles1511
      Synergy Research Group1511
      Quintiles1511
      PPD1511
      ICON1521
      PAREXEL1521
      INC Research1521
      Omnicare Clinical Research1521
      Pharm-Olam1521
      FOCUS Clinical Drug Development1531
      Global Clinical Trials1531
      PSI1531
    Key Issues1541
      Low Cost of Conducting Clinical Trials1541
      High Patient Recruitment Rate1541
      High Patient Compliance1541
      Good In and Out- Patient Facilities1551
      Increase in the Cost of Experienced Study Staff1551
      Limited Experience of Newly Qualified Sites1551
Innovative R&D Strategies and Models In-licensing, Virtual Pharma and Technology Aggregators1564
  Virtual Pharma Model1561
    Case Study 1: OncoHoldings1571
    Case Study 2: Regenicin1581
    Case Study 3: NovaQuest1581
    Technology Aggregators1581
  Developing Novel Compounds through Licensing1581
    Ono Pharmaceuticals and Concordia Pharmaceuticals1581
    AstraZeneca and Nektar1582
Innovative R&D Strategies and Models R&D Spin Offs1603
  Pharma R&D Spin Offs1611
    Case Study 1: GSK and Convergence Pharmaceuticals1611

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Innovative-R-D-Strategies-and-Models-Outsourcing-Strategic-Partnerships-and-Licensing-to-Improve-Productivity-and-Contain-Costs-2115-258>
  
APA:
GBI Research Reports. (2011). Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Innovative-R-D-Strategies-and-Models-Outsourcing-Strategic-Partnerships-and-Licensing-to-Improve-Productivity-and-Contain-Costs-2115-258>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.